After a three-year pause focused on operational standardization and integrating its single operating model and EMR system, LifeStance is returning to M&A execution in 2026. The strategy focuses on highly precise, disciplined tuck-in acquisitions to expand its outpatient footprint in existing Metropolitan Statistical Areas (MSAs) and grow specialized service lines.

Expected impact: Accelerates geographic density and market penetration while maintaining high integration speed and compliance alignment.

Following a comprehensive discovery process, LifeStance is implementing a new, best-in-class Electronic Health Record (EHR) system to replace legacy systems and support clinical and operational excellence.

Expected impact: Improves clinical workflows, enhances interoperability, and strengthens partnerships with major health systems.

Applying practical AI and digital tools across operations, including AI-assisted clinical documentation and advanced scheduling tools, to reduce administrative burdens on clinicians.

Expected impact: Improves patient access, enhances clinician experience and retention, and drives overall operating leverage.

Scaling high-margin, specialized interventional psychiatry treatments, specifically Spravato (esketamine nasal spray) and Transcranial Magnetic Stimulation (TMS).

Expected impact: Aims to generate $70 million in specialty services revenue in 2026, representing a 40% year-over-year increase, while diversifying clinical offerings.